ClinicalTrials.gg

Program

enpatoran

Also written as “M5049”, “Enpatoran” and “Enpatoran low dose”.

Its studies are mostly in Lupus Erythematosus, Systemic · Lupus Erythematosus, Cutaneous · Dermatomyositis · Renal Insufficiency · COVID-19, led by Merck KGaA, Darmstadt, Germany.

Furthest: phase 3, since Jan 9, 202612 company-led studies, 4 open or runningNext primary completion: Aug 12, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany124 open or runningphase 3since Jan 9, 2026Sep 17, 2018Aug 12, 2028phase 2 · NCT05540327

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2018First study: phase 1 study in HealthyFirst studyNCT03676322 · 96 enrolled · Germany
  2. Jun 25, 2020Phase 2 study in COVID-19NCT04448756 · 149 enrolled · United States, Brazil, Philippines
  3. Nov 23, 2020Phase 1 study in Lupus Erythematosus, SystemicNCT04647708 · 25 enrolled · Bulgaria, Germany, Moldova, Republic of and more
  4. May 5, 2021Phase 1 study in HealthyNCT04880213 · 36 enrolled · United Kingdom
  5. Dec 8, 2021Phase 2 study in Lupus Erythematosus, SystemicNCT05162586 · 456 enrolled · United States, Argentina, Australia and more
  6. Sep 12, 2022Phase 2 study in Lupus Erythematosus, SystemicNCT05540327 · 381 enrolled · United States, Argentina, Australia and more
  7. Dec 6, 2022Phase 2 study in DermatomyositisNCT05650567 · 20 enrolled · United States, Czechia, Greece and more
  8. Sep 6, 20242 phase 1 studiesNCT06589726, NCT06589713
  9. Jan 9, 20262 phase 3 studiesPhase 3 reachedNCT07332481, NCT07355218
  10. Sep 18, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07840287 · 404 planned · United States

Ahead

  1. Aug 12, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT05540327
  2. May 24, 2029Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT07332481
  3. May 25, 2029Primary completion: phase 3 study in Lupus Erythematosus, CutaneousNCT07355218
  4. Sep 1, 2031Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT07840287

TargetBeta

TLR7 →TLR8 →read by rule
“Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 314
afimetoranruleBristol-Myers Squibbphase 312

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07840287Lupus Erythematosus, Systemic · United States3RecruitingSep 1, 2031404
NCT07355218Lupus Erythematosus, Cutaneous · United States, Australia, Belgium and more3RecruitingMay 25, 2029202
NCT07332481Lupus Erythematosus, Systemic · United States, Australia, Belgium and more3RecruitingMay 24, 2029202
NCT06589726Healthy · Germany1CompletedDec 2, 202440
NCT06589713Renal Insufficiency · Germany1CompletedApr 13, 202634
NCT05650567Dermatomyositis · United States, Czechia, Greece and more2TerminatedJun 25, 202520
NCT05540327Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2Active, not recruitingAug 12, 2028381
NCT05162586Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedNov 20, 2024456
NCT04880213Healthy · United Kingdom1CompletedNov 23, 202136
NCT04647708Lupus Erythematosus, Systemic · Bulgaria, Germany, Moldova, Republic of and more1CompletedDec 19, 202325
NCT04448756COVID-19 · United States, Brazil, Philippines2CompletedAug 16, 2021149
NCT03676322Healthy · Germany1CompletedJul 26, 201996

How it is read

Names in the registry

  • “M5049”, 9 entries
  • “Enpatoran”, 4 entries
  • “Enpatoran low dose”, 2 entries
  • “Enpatoran high dose”, 2 entries
  • “M5049 low dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.